Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | CMA1 | P23946 | 13/20 | 0.44 |
| ▸ | ELANE | P08246 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | PREP | P48147 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27629823 | 1.00 | CTSL (0.49) | CTSLCTSBCTSKCMA1ELANE | |
| SCHEMBL6424293 | 1.00 | CTSL (0.49) | CTSLCTSBCTSKCMA1ELANE | |
| SCHEMBL6427701 | 1.00 | CTSL (0.49) | CTSLCTSBCTSKCMA1ELANE | |
| SCHEMBL6423730 | 0.83 | CTSL (0.54) | CTSLCTSBCTSKCMA1ELANE | |
| SCHEMBL6294320 | 0.83 | CTSL (0.53) | CTSLCTSBCTSKCMA1ELANE | |
| SCHEMBL13885550 | 0.83 | CTSL (0.53) | CTSLCTSBCTSKCMA1ELANE | |
| SCHEMBL8168155 | 0.81 | CMA1 (0.61) | CTSLCTSBCTSKCMA1ELANE | |
| SCHEMBL17378396 | 0.81 | CMA1 (0.61) | CTSLCTSBCTSKCMA1ELANE | |
| SCHEMBL4445986 | 0.81 | CMA1 (0.61) | CTSLCTSBCTSKCMA1ELANE | |
| SCHEMBL13258959 | 0.81 | CMA1 (0.51) | CTSLCTSBCTSKCMA1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612103-B2 | Such as 14-O-[4-hydroxy-N-valyl-piperidin-3-yl]-sulfanylacetylmutilin | NABRIVA THERAPEUTICS AG (AT) | 2009-11-03 | — | — | US | disclosed |
| EP-1534678-B1 | PLEUROMUTILIN DERIVATIVES AS ANTIMICROBBIALS | NABRIVA THERAPEUTICS FORSCHUNG (AT) | 2007-10-31 | — | — | EP | disclosed |
| US-20050250811-A1 | Such as 14-O-[4-hydroxy-N-valyl-piperidin-3-yl]-sulfanylacetylmutilin | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2005-11-10 | — | — | US | disclosed |
| EP-1534678-A1 | PLEUROMUTILIN DERIVATIVES AS ANTIMICROBBIALS | Sandoz AG (CH) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004011431-A1 | PLEUROMUTILIN DERIVATIVES AS ANTIMICROBBIALS | SANDOZ AG (CH) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250811-A1 | Such as 14-O-[4-hydroxy-N-valyl-piperidin-3-yl]-sulfanylacetylmutilin | ALK, AHR, ASPH | CTSL 1541/4885CTSB 3138/4885CTSK 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.